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Abstract
Patients with chronic kidney disease (CKD), who usually display low serum 25-
hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), are at high risk of
infection, notably those undergoing peritoneal dialysis (PD). We hypothesized that
peritoneal macrophages from PD patients are an important target for vitamin D-
induced antibacterial activity. Dialysate effluent fluid was obtained from 27 non-
infected PD patients. Flow cytometry indicated that PD cells were mainly monocytic
(37.9¡17.7% cells CD14+/CD45+). Ex vivo analyses showed that PD cells treated
with 25D (100 nM, 6 hrs) or 1,25D (5 nM, 6 hrs) induced mRNA for antibacterial
cathelicidin (CAMP) but conversely suppressed mRNA for hepcidin (HAMP). PD
cells from patients with peritonitis (n53) showed higher baseline expression of
CAMP (18-fold¡9, p,0.05) and HAMP (64-fold¡7) relative to cells from non-
infected patients. In 12 non-infected PD patients, oral supplementation with a single
dose of vitamin D2 (100,000 IU) increased serum levels of 25D from 18¡8 to
41¡15 ng/ml (p50.002). This had no significant effect on PD cell CD14/CD45
expression, but mRNA for HAMP was suppressed significantly (0.5-fold, p50.04).
Adjustment for PD cell CD14/CD45 expression using a mixed linear statistical
model also revealed increased expression of CAMP (mRNA in PD cells and protein
in effluent) in vitamin D-supplemented patients. These data show for the first time
that vitamin D supplementation in vitro and in vivo promotes innate immune
responses that may enhance macrophage antibacterial responses in patients
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undergoing PD. This highlights a potentially important function for vitamin D in
preventing infection-related complications in CKD.
Introduction
In patients with chronic kidney disease (CKD), vitamin D-deficiency is a
persistent problem [1, 2]. Current guidelines for the management of adult and
pediatric CKD alterations of bone and mineral metabolism recommend target
levels for 25-hydroxyvitamin D (25D), the major circulating form of vitamin D, of
at least 20 ng/mL (50 nM) [3–5]. Despite this, vitamin D deficiency remains
common in CKD patients [6], most notably in pediatric patients where a 40–80%
prevalence of low serum 25D has been reported [7–12]. Previously the
management of vitamin D-deficiency in CKD was focused on the use of active
1,25-dihydroxyvitamin D (1,25D) to control secondary hyperparathyroidism and
associated skeletal/calciotropic dysfunction [13], although supplementation with
vitamin D itself has been shown to delay the onset of secondary hyperparathyr-
oidism [10]. Other studies highlighting diverse effects of vitamin D on
cardiovascular [14, 15] and immune function [16, 17] support broader benefits of
vitamin D supplementation in CKD patients [18]. Conversely, vitamin D-
deficiency may impair key extra-renal responses to vitamin D, notably innate
immune responses to infection [19, 20].
Patients with CKD are at high risk of infection [21], notably those undergoing
peritoneal dialysis (PD) [22–24]. Immune responses in the peritoneum are of
immediate relevance to PD patients because of their close link with important
morbidities such as peritonitis and the increased risk of further treatment failure
[25]. The peritoneum has abundant cells capable of supporting immune response
to peritoneal infection [26], with the predominant cell type being macrophage-
like [27–29]. Macrophages are key target cells for vitamin D, with intracrine
expression of the enzyme 1a-hydroxylase (CYP27B1) catalyzing local synthesis of
1,25D, which is then able to transcriptionally regulate key antimicrobial proteins
such as cathelicidin (CAMP), as well as classical targets such as its catabolic
enzyme 24-hydroxylase (CYP24A1), via the nuclear vitamin D receptor (VDR)
[30]. Recent studies have shown that 25D and 1,25D also act to decrease
expression of another antibacterial protein, hepcidin (HAMP), resulting in
increased expression of ferroportin, the only known exporter of intracellular iron
[31]. This suggests an alternative antibacterial function for vitamin D involving
suppression of intracellular iron concentrations. Based on these observations we
postulated that vitamin D (25D)-deficiency associated with CKD may predispose
to infection through impaired regulation of CAMP and HAMP activity.
In a case-control study of adult patients undergoing hemodialysis, low serum
levels of cathelicidin protein (hCAP) was an independent risk factor for death due
to infection, with serum hCAP correlating with circulating 1,25D but not 25D
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[32]. Paradoxically, other studies have shown that vitamin D therapy decreased
expression of CAMP in peripheral blood mononuclear cells [33]. In both cases the
apparent lack of 25D-mediated induction of hCAP/CAMP was attributed to the
absence of patient infection and associated induction of CYP27B1. However, it
seems unlikely that intracrine induction of innate immunity by 25D will be
manifested by changes in circulating levels of antibacterial proteins, but will
instead reflect localized effects on tissue macrophages at sites of infection. With
this in mind, we hypothesized that peritoneal cells may provide a more sensitive
indicator of innate immune responses to altered 25D status in PD patients. These
cells are not routinely used to assess immune function because protocols for
isolating cells from dialysate effluent are time consuming [34–38]. Nevertheless,
previous studies have shown that PD cells express a functional system for
synthesis of 1,25D [39], with this activity being greatly enhanced in cells from
patients with peritonitis [39, 40]. We therefore investigated the capacity for
vitamin D-mediated intracrine regulation of antibacterial CAMP and HAMP in
PD cells ex vivo and in vivo. Activation of such a mechanism may enhance innate
immune activity in CKD patients and thus help to prevent infection and
associated morbidities.
Results
Clinical characteristics, serum biochemistry, and PD cell
phenotype/gene expression in dialyzed patients
Baseline data for all the patients studied are shown in Table 1 (this includes the
first baseline sample for the subset of patients who subsequently participated in
the vitamin D supplementation trial), and the underlying renal diseases associated
with the patient cohort are summarized in Table S1 in S1 File. Serum
concentrations of 25D were 18¡8 ng/ml. Flow cytometry indicated that PD cells
were mainly monocytic/macrophage-like, with 37.9¡17.7% being CD14+/CD45+,
while 25.4¡14.5% were CD142/CD45+ and 32.1¡19.9% were CD142/CD452.
Linear regression analyses using baseline samples showed that there was no
significant correlation between PD cell expression of CD14 and CD45 and patient
serum 25D levels (data not shown). However, there was an inverse correlation
between PD cell CYP27B1 and VDR mRNA, and the number of CD142/CD45+
cells (R50.429, p50.014 and R50.358, p50.037 respectively) (Figures S1A and
1C in S2 File). Collectively these data suggest that expression of the intracrine
vitamin D system is linked to CD14 expression.
Baseline data were further analyzed to assess the relationship between PD cell
type, serum 25D, and the intracrine vitamin D system on three markers of PD cell
immune function: 1) PD cell mRNA for CAMP; 2) PD cell mRNA for HAMP; 3)
hCAP protein concentrations in PD dialysate effluent. There was no significant
correlation between PD cell CD14/CD45 expression and any of these markers
(data not shown), and no significant correlation between baseline serum
concentrations of 25D and PD cell mRNA for CAMP or HAMP (Fig. 1A).
Vitamin D and Peritoneal Macrophages
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However, PD cell mRNA for CYP27B1 correlated with both CAMP (R50.737,
P,0.001), and HAMP (R50.544, P50.047) (Fig. 1B). By contrast, PD cell VDR
did not correlate with CAMP or HAMP (Fig. 1C). Similar analysis of hCAP
concentrations in dialysate effluent showed no correlation with PD cell type or
any of the PD cell mRNAs analyzed in Fig. 1 (data not shown).
Effects of vitamin D metabolites on PD cell gene expression
ex vivo
Ex vivo treatment of PD cells from non-infected patients with 25D or 1,25D
increased expression of CAMP, with 1,25D (1729-fold, p,0.001) (Fig. 2A) being
more potent than 25D (2.81-fold, p,0.001) (Fig. 2B). By contrast, both 1,25D
and 25D suppressed expression of HAMP to a similar extent (0.57-fold, p,0.05
and 0.52-fold, p,0.05 respectively) (Fig. 2A and 2B).
Table 1. Clinical and biological data for PD patients at baseline.
Patients Number of patients (pediatric/adults) 27 (19/8)
Age (years) 18.1 (2.7–39.1)
Number of males (pediatric/adults) 16 (12/4)
Dialysis duration (years) 2.7 (0.1–12.1)
KT/V at the time of evaluation 2.1¡0.9
Baseline biological data Serum calcium (mg/dL) 8.8¡1.0
Serum phosphorus (mg/dL) 5.1¡0.9
Serum PTH (pg/mL) 418 (24–1571)
Serum 25D (ng/mL) 18 (8–55)
Serum total alkaline phosphatase (IU/L) 148 (57–788)
Serum albumin (g/L) 42¡5
Serum hemoglobin (g/dL) 11.9¡2.2
Serum BUN (mg/dL) 45.4¡16.4
Serum ferritin (mg/L) 314 (35–1106)
Plasma FGF23 (RU/mL) 2902 (307–42505)
Peritoneal dialysate FGF23 (RU/mL) 69 (11–472)
Peritoneal dialysate hCAP (pg/ml) 2.2 (0.4–7.7)
PD cell analyses CD14+/CD45+ monocyte/macrophage (% of cells) 38¡18
CD142/CD452 non-leukocyte (% of cells) 32¡20
CD45+/CD142 non-monocytic (% of cells) 25¡15
CYP27B1 (DCt) 16.2¡1.6
CYP24A1 (DCt) 20.0¡2.9
VDR (DCt) 14.7 (11.2–20.6)
CAMP (DCt) 22.1¡1.5
HAMP (DCt) 17.8¡1.6
Expression or lack of expression of CD14 and CD45 is shown as % of CD142/+ or CD452/+ PD cells. Expression of mRNAs for CYP27B1, CYP24A1, VDR,
CAMP, and HAMP, are shown as DCt values relative to expression of the housekeeping gene 18S rRNA, the lower the DCt the higher the expression of the
gene of interest. Data are presented as mean ¡ SD for variables with normal distributions, or median (range) for variables with skewed distribution.
doi:10.1371/journal.pone.0116530.t001
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Analysis of PD cells from a subset of patients with peritonitis
PD cells from patients with peritonitis (n53) showed increased expression of
CYP27B1 relative to PD cells from non-infected patients (4.97-fold higher¡2.75,
p,0.01) (Fig. 3A). There was no significant difference in VDR expression between
the two patient groups, but the catabolic enzyme CYP24A1 was lower in PD cells
from peritonitis patients (0.11-fold¡0.31, p,0.05). Expression of both CAMP
Fig. 1. Vitamin D-related gene expression in CKD patient PD cells at baseline. Correlation between PD
cell mRNA expression of CAMP or HAMP and: A) donor patient serum concentrations of 25D (ng/ml); B)
CYP27B1 mRNA; C) VDR mRNA in PD cells isolated from CKD patient dialysate effluents from n527
baseline samples (pre-vitamin D supplementation) from 27 different patients. Data for mRNA expression are
shown as 1/DCt values.
doi:10.1371/journal.pone.0116530.g001
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(18.3-fold¡9.4, p,0.01), and HAMP (64.1-fold¡7.0, p,0.001) was increased in
peritonitis PD cells from compared to non-infected patients. Elevated hCAP
protein was also observed in dialysate effluent. This measurement was only
available for two peritonitis samples but, in contrast to the low levels of hCAP
observed in dialysate from non-infected patients (median 2.24, range 0.37–7.67
pg/mL), the acute peritonitis samples showed 12.6 and 131.8 pg/mL hCAP
respectively. Data in Fig. 3B showed that CAMP expression in peritonitis PD cells
was further elevated following ex vivo treatment with 1,25D (135.3-fold¡24.9,
p,0.01) or 25D (34.2-fold¡5.2, p,0.01). For HAMP, 25D or 1,25D treatments
were equally effective in suppressing expression (0.28-fold¡0.12, p,0.01 and
0.31-fold¡0.30, p,0.01 respectively).
Fig. 2. Effect of 25D and 1,25D on vitamin D-related gene expression in baseline PD cells in vitro. Effect
of 1,25D (5 nM, 6 hrs, n513) (A) or 25D (100 nM, 6 hrs, n58) (B) on expression for mRNA for CYP27B1,
VDR, CAMP and HAMP in PD cells cultured in RPMI with 10% human serum and GM-CSF (10 IU/mL). Data
are shown as fold-change in mRNA expression relative to vehicle (0.1% ethanol)-treated cells for each gene
with vehicle expression51 (see dashed line). *5statistically different from vehicle-treated cells, p,0.05.
***5statistically different from vehicle-treated cells, p,0.001.
doi:10.1371/journal.pone.0116530.g002
Fig. 3. Baseline expression, and 25D/1,25D-regulation of vitamin D-related genes in PD cells from
patients with peritonitis. (A) Relative expression of mRNA for CYP27B1, VDR, CYP24A1, CAMP and
HAMP in PD cells from peritonitis patients (n53) compared to PD cells from non-infected patients (n58). Data
are shown as fold-change in mRNA expression relative to non-infected cells. (B) Effect of 1,25D (5 nM, 6hrs)
or 25D (100 nM, 6 hrs) on expression for mRNA for CAMP (grey bars) or HAMP (black bars) in PD cells from
peritonitis patients (n53) RPMI with 10% human serum and GM-CSF (10 IU/mL). Data are shown as fold-
change in mRNA expression relative to non-infected PD cells (3A) or vehicle (0.1% ethanol)-treated cells (3B).
*5statistically different from vehicle-treated (0.1% ethanol) cells, p,0.05. **5statistically different from
vehicle-treated cells, p,0.01.
doi:10.1371/journal.pone.0116530.g003
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Effect of vitamin D supplementation in vivo on PD cell phenotype
and gene expression
To explore vitamin D and PD cell immune function in vivo, further studies were
carried out using dialysate effluent samples from twelve patients who completed a
pilot vitamin D supplementation trial, in which serum levels of 25D in baseline
sample 1 (B1) and B2 respectively increased from 17.5 (13.5–24.5) ng/ml, and 16.0
(10.0–23.5) ng/ml, to 41.5 (27.5–43.0) ng/ml (p50.002) (Table 2), with a one
month period between B1 and B2. Serum PTH and FGF23 were unchanged from
baseline following vitamin D supplementation, and there was no change in PD cell
CD14/CD45 expression. Basic statistical analysis also revealed no significant effect
of vitamin D supplementation on PD cell mRNA for CAMP, but PD cells showed
lower levels of HAMP (0.5-fold, p50.002) following vitamin D supplementation.
To account for variations in cells expressing CD14/CD45 in each sample, further
statistical analysis of CAMP and hCAP expression was carried out using Mixed
Linear Modeling. After adjustment for CD142/CD45+ cells, there was a significant
increase in PD cell expression of CAMP following vitamin D supplementation
(1.85-fold, P50.03) (Table S2 in S1 File). Additional adjustment for age yielded a
similar result (Table S2 in S1 File). Adjustment for numbers of CD142/CD45+ or
CD14+/CD45+ cells also revealed an increase in the concentrations of dialysate
hCAP protein following vitamin D supplementation (p50.02 for both models)
(Table S3 in S1 File).
Discussion
Intracrine conversion of 25D to active 1,25D appears to be a pivotal mechanism in
vitamin D-mediated regulation of monocyte/macrophage antibacterial activity
[20], with this response being compromised under conditions of vitamin D-
deficiency [30], but enhanced upon restoration of serum 25D levels following
vitamin D supplementation [41]. Intracrine innate immune responses to 25D
include enhanced autophagy [42], and induction of antibacterial proteins such as
cathelicidin [30] and b-defensin 2 [43]. More recently we have shown that 25D
can also promote innate immune activity in macrophages by suppressing
expression of another antibacterial protein, hepcidin, encoded by the HAMP gene
[31]. Expression of HAMP mRNA was 60-times higher in PD cells from
peritonitis patients relative to uninfected patients. This is consistent with
previously reviewed responses to infection [44], and may be part of a program of
peritoneal antibacterial responses, with CAMP also being induced (18-fold) in PD
cells from patients with peritonitis. Furthermore, in the two peritonitis samples
available for measuring concentrations of hCAP protein in dialysate effluent,
hCAP concentrations were also elevated relative to uninfected patients, suggesting
that PD macrophages are the source of the dialysate hCAP. Although the data
from peritonitis samples are promising, it will be important in future studies to
carry out prospective analyses using larger cohorts of infected peritoneal dialysis
patients.
Vitamin D and Peritoneal Macrophages
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Table 2. Serum biochemistry, PD cell flow cytometry and PD cell gene expression in CKD patients before and after supplementation with vitamin D2.
Variable Time point Median (IQR)
Comparison between
baseline samples, p*
Comparison between first
baseline and post- treatment
samples, p*
Flow cytometry CD14– B1 (21 month) 24.6 (16.8–38.5) 0.3 0.2
CD45+ (% of cells) B2 (0 month) 20.7 (12.9–23.7)
non-monocytic TT (+1 month) 15.2 (4.7–19.8)
CD14+ B1 38.6 (19.2–52.7) 0.01 0.2
CD45+ (% of cells) B2 53.2 (24.8–58.8)
monocyte/macrophage TT 61.2 (24.7–81.9)
CD142 B1 23.4 (15.4–54.1) 0.2 1.0
CD452 (% of cells)
non-leukocyte
B2 21.2 (16.4–24.3)
TT 19.3 (10.5–38.1)
mRNA expression
(DCt)
CYP24A1 (DCt) B1 20.4 (18.2–21.9) 0.4 0.8
B2 20.0 (18.5–22.2)
TT 21.6 (18.8–22.1)
CYP27B1 (DCt) B1 17.1 (16.8–18.0) 0.1 0.8
B2 17.3 (16.9–18.5)
TT 17.6 (16.4–18.4)
VDR (DCt) B1 13.3 (12.5–17.0) 0.4 0.8
B2 13.2 (12.7–17.6)
TT 13.5 (12.2–16.8)
LL37 (DCt) B1 23.0 (22.6–24.0) 0.4 0.4
B2 23.3 (22.4–23.7)
TT 23.1 (20.9–23.5)
HAMP (DCt) B1 17.9 (16.9–19.3) 0.5 0.04 (0.5-fold decrease)
B2 18.2 (17.5–20.0)
TT 18.9 (17.4–19.6)
Blood markers FGF 23 (RU/mL) B1 3302 (1812–10511) 0.3 0.08
B2 2982 (1753–6362)
TT 1957 (1317–9461)
PTH (pg/mL) B1 201 (41–699) 0.9 0.4
B2 190 (54–486)
TT 276(38–447)
25D (ng/mL) B1 17.5 (13.5–24.5) 0.8 0.002 (2.37-fold increase)
B2 16.0 (10.0–23.5)
TT 41.5 (27.5–43.0)
Dialysate hCAP (pg/ml) B1 2.8 (1.9–6.4) 0.5 1.0
B2 3.0 (1.4–7.9)
TT 3.6 (1.5–6.0)
FGF23 (RU/mL) B1 86.5 (34.5–120.5) 0.2 0.2
B2 53.0 (28.5–76.5)
TT 60.5 (29.0–107.5)
Vitamin D and Peritoneal Macrophages
PLOS ONE | DOI:10.1371/journal.pone.0116530 December 30, 2014 8 / 18
The key function of hepcidin appears to be the suppression of cell membrane
expression of ferroportin, the only known exporter of intracellular iron [45]. The
hepcidin-ferroportin axis in cells such as enterocytes, hepatocytes and macro-
phages plays a key role in the hypoferremia of infection [46]. Pathogens such as
bacteria utilize iron to maintain growth, and thus restriction of circulating iron
concentrations represents an important host response to systemic infection [47].
Conversely, intracellular accumulation of iron can promote bacterial growth
within cells, and thus additional mechanisms may be required to combat
intracellular infection. Data presented in the current study strongly support a role
for vitamin D as a sensitive regulator of hepcidin in peritoneal macrophages, with
this effect complementing more established induction of antibacterial CAMP/
hCAP.
There was no significant correlation between baseline patient serum 25D levels
and PD cell CAMP or HAMP. This is possibly due to the low circulating levels of
25D in this population (,20 ng/ml), but could also be influenced by expression
of the machinery for 25D activation and 1,25D signaling. At baseline, PD cell
CAMP and HAMP correlated significantly with expression of the 25D-activating
enzyme CYP27B1 (Fig. 1). Baseline variations in the vitamin D system may be due
to intra-individual exposure to immune stimulators capable of activating
pathogen-sensing mechanisms such as the TLR system [48]. This is endorsed by
the increased expression of CYP27B1 and decreased expression of CYP24A1 in PD
cells from peritonitis patients. In PD cells from non-infected patients CYP27B1
expression may also be influenced by factors associated with CKD. Plasma levels
of FGF23 correlated strongly with the FGF23 in dialysate effluents (Figure S2 in S2
File), but there was no correlation between FGF23 and either its known target,
CYP27B1, or immune markers such as HAMP and CAMP. This may be due to the
relatively low levels of CYP27B1 and CAMP expression in PD cells from non-
infected patients, and it will be interesting in future studies to assess the possible
impact of FGF23 on vitamin D-mediated immune responses in patients with
peritonitis.
It is also important to recognize that some patients with end stage renal disease
active vitamin D (calcitriol or synthetic vitamin D analog) therapy to help control
secondary hyperparathyroidism. In the current study, 8 of the 12 patients who
took part in the vitamin D supplementation pilot study were receiving calcitriol/
analog therapy. Although the numbers of patients not receiving calcitriol/analog
therapy was low, analysis of the two groups of patients suggested that this had no
effect on the efficacy of vitamin D supplementation in raising serum
concentrations of 25D (Figure S3A in S2 File). However, intriguingly, patients
who did not receive calcitriol/analog therapy showed a stronger suppression of
Expression or lack of expression of CD14 and CD45 is shown as % of CD142/+ or CD452/+ PD cells. Expression of mRNAs for CYP27B1, CYP24A1, VDR,
CAMP and HAMP, are shown as DCt values relative to housekeeping gene 18S rRNA, the lower the DCt the higher the expression of the gene of interest.
Time points: Baseline 1 (B1, 21 month), baseline 2 (B2, 0 month), post-treatment (TT, +1 month). Results show median (inter-quartile range) values. *A
Kruskall Wallis non parametric test was used to compare baseline samples, and baseline 1 with post- treatment samples.
doi:10.1371/journal.pone.0116530.t002
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hepcidin relative to treated patients (Figure S3B in S2 File). A possible mechanism
for this is unclear as there did not appear to be any significant difference between
the calctriol/analog-treated and untreated groups for expression of components of
the vitamin D system (data not shown). Similarly, stratifying the patients
according to calcitriol/analog therapy did not appear to have any impact on
expression of CAMP (data not shown). However, although the numbers of
patients in the therapy groups is small, these data suggest that effects of vitamin D
supplementation, and raised serum 25D, occur irrespective of underlying therapy
with active vitamin D. This provides further support for an intracrine model of
vitamin D-mediated immunity involving localized synthesis of 1,25D, and will be
a key feature of future studies of vitamin D supplementation in kidney disease.
Other variables that may also influence the immune impact of vitamin D
supplementation in dialysis patients include the underlying cause of the renal
disease, and residual renal function. Although we were unable to show any
significant effect of these parameters on patient responses following vitamin D
supplementation, residual renal function did show some associations for baseline
data (Table S4 in S1 File). As expected, patients with residual renal function had
decreased circulating concentrations of FGF23 and lower serum levels of
creatinine. They were also significantly younger, were on dialysis for less time, had
decreased PD monocyte expression of CYP24A1 mRNA, but had higher PD
monocyte mRNA for CAMP. This potential link between residual renal function,
and attenuated peritoneal monocyte catabolism of vitamin D and enhanced
antibacterial expression will be another important target for future studies.
Inter-patient variations in PD cell expression of the vitamin D system may also
be due to the composition of cells present in the peritoneum during dialysis. Both
CD14+ macrophages and CD142 neutrophils express CAMP [49, 50] but, unlike
macrophages, neutrophils do not appear to synthesize 1,25D. As such these cells
are unlikely to be affected by changes in 25D concentration but will nevertheless
contribute to PD cell expression of CAMP, with this effect varying depending on
individual dialysate neutrophil levels. It was therefore interesting to note that
following supplementation with vitamin D in vivo, a significant increase in PD
cell expression of CAMP was only observed following adjustment for CD142
expression. This contrasts the in vivo vitamin D suppression of PD cell HAMP
without adjustment for cell phenotype, which can be explained by the
predominant expression of this gene in CYP27B1-expressing macrophages. In the
context of monocyte expression of HAMP, it was interesting to note that dual
expression of the monocyte marker CD14 and common leukocyte antigen CD45
was statistically different between baseline samples 1 and 2 (Table 2). This
underlines the wide inter-patient variations in peritoneal immune cells, but also
further endorses the suppression of HAMP expression, relative to baseline sample
1, following vitamin D supplementation. In essence, the apparent higher numbers
of monocytic (CD14+/CD45+), HAMP-expressing, cells in B2 would enhance the
possibility of vitamin D-mediated suppression of HAMP. The fact that HAMP
expression was suppressed by vitamin D supplementation without any adjustment
for immune cell population highlights the importance of this antibacterial
Vitamin D and Peritoneal Macrophages
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pathway for vitamin D, particularly in the context of kidney disease. The ability of
PD cells to mount an adequate antibacterial response to infection may therefore
be dependent on their immune composition as well as the local concentration of
25D. In this regard it was interesting to note that analysis of the dialysate effluent
samples did not reveal any detectable 25D (data not shown). This suggests that
exposure to elevated concentrations of 25D occurs in the general circulation, with
the resulting monocytes migrating across the peritoneal membrane into the
peritoneal cavity.
Previous studies primarily focused on ex vivo analyses have hypothesized a role
for vitamin D in promoting antibacterial immune responses. By analyzing in vivo
responses to supplementation with vitamin D, the current study supports this
hypothesis, whilst also highlighting some of the limitations of ex vivo analyses.
Data suggest that PD cells are an important target for vitamin D, with enhanced
25D promoting antibacterial CAMP and suppressing iron-regulatory HAMP. PD
cells show similar expression of the vitamin D intracrine sytem (CYP27B1/VDR)
relative to peripheral blood mononuclear cells [51]. It therefore seems likely that
responses to 25D in vivo will be highly efficient at barrier sites such as the
peritoneum where macrophages make up a greater proportion of the total cell
population, and where they are more likely to encounter a pathogen. In this
setting, despite no apparent infection, patients may nevertheless demonstrate
enhanced antibacterial responses when serum 25D levels are elevated and this may
help to prevent more widespread infection in PD patients. Less clear is whether
vitamin D status or supplementation will have an impact on innate immune
responses following peritoneal infection. Further clinical studies are required to
determine the extent to which acute vitamin D supplementation and/or
therapeutic vitamin D analogs may help to prevent and/or treat infection
associated with CKD.
Materials and Methods
Patients
We recruited children and young adults (below 40 years of age) undergoing PD,
and followed in the Davita Dialysis Center at UCLA, to participate in a study to
collect PD effluents and assess circulating markers of bone and mineral
metabolism, PD cell phenotype and gene expression. A pilot vitamin D
supplementation trial was also carried out in a subset of patients. The project was
approved by the UCLA ethic committee, referred to as the Institutional Review
Board (ethics approval#10-07-003-01). Patients and their parents/caregivers gave
written consent before enrollment. Original copies of the written consent are
stored within the administrative offices of the Division of Pediatric Nephrology at
the David Geffen School of Medicine at UCLA.
Baseline data were obtained in 19 children and 8 young adults. Patients were
treated with continuous cycling peritoneal dialysis using a standard double-bag
dialysate system, with 1.36% glucose dialysate. All patients had been free of
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peritonitis and growth hormone therapy for at least 3 months prior to sample
collection. In addition they were not receiving, antibiotics, corticosteroids or
other immunosuppressing medications at the time of sample collection. Three
separate patients with acute peritonitis episodes were studied at baseline to
evaluate the impact of acute infections on the main parameters assessed in this
study. Of the 19 children and 8 young adults who were assessed at baseline, 7
children and 5 adults successfully completed a pilot study to assess the impact of
oral vitamin D supplementation. Patients above 25 kg received 50,000 IU vitamin
D2 twice a week for 4 weeks, and those below 25 kg weight received 50,000 IU
once a week for 4 weeks. Patients served as their own controls: for each patient,
two serum and PD dialysate samples were obtained before vitamin D
supplementation (Month 21, Month 0), and a third sample was then obtained
after one month of vitamin D2 therapy. Circulating levels of 25D, PTH, and
FGF23 were measured with an RIA kit, a first-generation immunometric assay
(Immutopics San Clemente, CA, normal range 10–65 pg/mL) and a 2nd
generation C-terminal kit (Immutopics San Clemente, CA), respectively.
Concentrations of hCAP in dialysate effluent were measured with a specific ELISA
as described previously [52].
Isolation of PD cells from dialysate effluent
Peritoneal dialysate effluents were collected using previously described protocols
[51]. Briefly, an initial dialysate aliquot (10 mL) was stored at 280 C˚ for
measurement of FGF23 and hCAP. For isolation of PD cells, total overnight
dialysate effluents were decanted into 500 ml sterile centrifuge tubes, and then
centrifuged at 1200G for 10 mins at room temperature. Supernatants were
discarded and cell pellets were combined and re-centrifuged using the same
parameters. Viable cells were counted in a haemocytometer after staining with
Trypan blue. After a third centrifugation remaining cells were either: 1) treated
with RNAzol and frozen at 280 C˚; 2) prepared for flow cytometric analysis; 3)
used for ex vivo culture.
Flow cytometry
Monoclonal antibodies against CD45 (common leukocyte antigen) and CD14
(monocyte marker) conjugated with FITC and R-PE (MHCD-4501 and MHCD-
1404) respectively (Invitrogen Corporation, Camarillo, CA, USA) were used for
flow cytometric analysis of immune cell phenotype of PD cells. Cells were
analyzed using a FACS Caliber flow cytometer (BD LSRII and FACS-DIVA
software, Becton-Dickinson, Franklin Lakes, NJ, USA).
Culture of PD macrophages
PD cells were seeded at 1–56106 cells/mL in medium containing RPMI 1640,
10% human serum (HS, Human AB serum, Omega Scientific, Tarzana, CA, USA)
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in 12-well plastic culture plates. After 12–15 hrs of culture to ensure attachment of
monocytes, cells were washed once with medium and then re-incubated in RPMI
with 10% HS and GM-CSF 10 IU/mL (PeproTech Inc., Rocky Hood, NJ, USA).
Treatments were carried out using 25D (100 nM), 1,25D (5 nM), or vehicle
(ethanol 0.1%), for 6 hrs, at 37 C˚ in 5% CO2. After incubation cells were lysed
with RNAzol and RNA analyzed by quantitative RT-PCR (qRT-PCR) as described
below.
Extraction of RNA and reverse transcription
RNA was extracted as described previously [51]. Aliquots (300 ng) of RNA in
RNase-free water were reverse-transcribed as recommended by the manufacturer
(SuperScript III Reverse Transcriptase, Invitrogen, Carlsbad, CA), and as
previously described [51].
qRT-PCR amplification of cDNAs
Expression of mRNAs for VDR, CYP27B1, 24-hydroxylase (CYP24A1), CAMP and
HAMP was quantified as previously described [51]. Approximately 7.5 ng of
cDNA was used per reaction. All reactions were normalized by multiplex analysis
with the housekeeping 18S rRNA gene (Applied Biosystems, Foster City, CA,
USA). Data were obtained as Ct values (cycle number at which logarithmic PCR
plots cross a calculated threshold line). DCt values, corresponding to the
difference between the Ct of the target gene and the Ct of the housekeeping 18S
rRNA gene, were then calculated. PCR amplification of cDNA was conducted
using Taqman gene expression assays, as previously described [51]. Probe and
primer sets were as follows: Hs00172113-m1 (VDR), Hs00168017-m1 (CYP27B1),
Hs00167999-m1 (CYP24A1), Hs00189038-m1 (CAMP) and Hs00221783_m1
(HAMP) (Applied Biosystems). All reactions were amplified under the following
conditions: 95 C˚ for 10 mins, 40 cycles of 95 C˚ for 30 seconds, 55 C˚ for 1 min
and 72 C˚ for 1 min. Reactions were initially expressed as mean¡ SD DCt values
and these data were used for all statistical analyses. Values for fold-change relative
to vehicle-treated cells were determined using the equation 22 DCt. For correlation
analyses, data were also shown as 1/DCt values to more conveniently represent
mRNA expression.
Statistical analysis
Data are presented as mean¡SD for variables with normal distributions, or
median (range) for variables with skewed distribution. For all baseline data,
analysis of relationships between continuous variables was carried out using the
Spearman correlation test for bivariate analyses, and non-parametric tests for
comparing distributions. For the pilot supplementation study, two sets of patient
samples were obtained at baseline with a one-month interval between samples. A
further treatment sample was obtained after one month of vitamin D therapy so
Vitamin D and Peritoneal Macrophages
PLOS ONE | DOI:10.1371/journal.pone.0116530 December 30, 2014 13 / 18
that each patient served as his/her own control. The first sample obtained at
baseline served as control for comparison between the two baseline samples, and
also for comparison with the post-treatment sample. The effects of supplemental
vitamin D on genes of interest as well as peritoneal and circulating biomarkers
were then analysed by using non-parametric tests for matched data. As CAMP is
expressed by both macrophages (CD45+ and CD14+) and neutrophils (CD45+ and
CD142), the effects of supplemental vitamin D on CAMP mRNA expression and
peritoneal hCAP concentrations were analysed by using a mixed linear model,
which is a hierarchical method based on measurements (samples) made over time
and on clusters of related statistical units (i.e. patients). This takes into account
that samples over time from the same patient are not independent, and adjusts on
variables that vary at the sample level (e.g. CD14/CD45 expression) or at the
patient level (e.g. age). The impact of vitamin D treatment on CAMP mRNA
expression and peritoneal hCAP concentration respectively were thus analysed,
adjusted on CD142/CD45+ expression, and age. The model results in coefficients
(95% CI) estimating the impact of supplemental vitamin D adjusted on individual
group-level co-variables, and taking into account the dependence of samples from
a same patient. This model is a generalized linear multilevel model, so no linearity
or normality assumptions were made. All statistical tests were performed at the
two-sided 0.05 level of significance while an alpha of 0.10 was considered
significant in multiple regression analyses. Analyses were performed using SPSS
software 19.0 (SPSS Inc., Chicago) for Windows, and Stata 11/SE software
(Statacorp LP, Texas).
Supporting Information
S1 File. Supporting tables. Table S1, Underlying primary renal disease leading for
each patient in the baseline data and pilot study. Table S2, General linear mixed
modelling for cathelicidin (CAMP) mRNA expression. In all models, samples were
clustered within patients (ie. considered as a group-level variable). The glm Stata
procedure was used, modelling with random effects. Results were presented as
coefficient (95% CI); p-value only if significant according to the model run. Each
line corresponds to a separate modelling, All genes expression data were tested
separately, with adjustment variables defined in the 1st column. *No adjustment
on paediatric state for this model. The statistical analyses were made with raw DCt
of mRNA expression; since a greater DCt corresponds to a decreased mRNA
expression, a negative result corresponds to an increased expression of the gene of
interest. Table S3, General linear Mixed modelling for cathelicidin protein (hCAP)
concentration in the peritoneal dialysis effluent. In all models, samples were
clustered within patients (ie. considered as a group-level variable). The glm Stata
procedure was used, modelling with random effects. Results were presented as
coefficient (95% CI); p-value. Each line corresponds to a separate modelling, and
adjustment variables are defined in the 1st column. *No adjustment on paediatric
state for this model. Table S4, Effect of residual renal function at baseline.
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Correlation analyses were carried out using data for baseline sample 1, and
analysed using Mann-Whitney-Wilcoxon tests.
doi:10.1371/journal.pone.0116530.s001 (DOCX)
S2 File. Supporting figures. Figure S1, Expression of vitamin D-related genes
relative to CD14 and CD45 expression by cells isolated from peritoneal dialysate
effluent. Correlation between mRNA expression for: A&B) CYP27B1; C&D) VDR;
E&F) CYP24A1 and percentage of PD cells that are non-monocytic (CD142) (A,
C, E) or monocytic (CD14+) (B, D, F). PD cells were isolated from CKD patient
dialysate effluents from n540 baseline samples from 27 different patients (pre-
vitamin D supplementation). Data for mRNA expression are shown as 1/DCt
values. Figure S2, Correlation between concentrations of plasma fibroblast growth
factor 23 (FGF23) and FGF23 in peritoneal dialysate effluent. Figure S3, Effect of
therapeutic use of active calcitriol or vitamin D analog therapy on responses to
vitamin D supplementation in the pilot study. Of the 12 patients who participated
in the vitamin D supplementation pilot study, 8 were receiving therapy with active
calcitriol or vitamin D analogs (analog therapy). A) serum concentrations of 25D
(ng/ml) in patients at baseline 1 (B1), baseline 2 (B2) or following vitamin D
supplementation (TT) according to use of analog therapy or no therapy. B) fold-
suppression of hepcidin (HAMP) mRNA expression in peritoneal monocyte/
macrophages following vitamin D supplementation (relative to cells from B1
samples), according to use of analog therapy or no therapy. **5statistically
different from analog therapy, p,0.01 (students t-test).
doi:10.1371/journal.pone.0116530.s002 (DOCX)
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